Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
1
Bullish
10
Bearish
35
Neutral
1
Bullish
10
Bearish
32
Neutral
0
Bullish
0
Bearish
3
Neutral
1
Bullish
10
Bearish
3
Neutral
1
Bullish
10
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Investor Presentation
Q3 FY25
Investor Presentation
Q1 FY25
Investor Presentation
Q3 FY24
Investor Presentation
Q1 FY24
Discovery themes featuring this stockSudarshan Pharma Industries Ltd (SUDARSHAN) is currently trading at 32.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Sudarshan Pharma Industries Limited is a specialty chemicals and pharmaceutical manufacturing, sourcing and trading company focused on APIs, advanced intermediates, specialty chemicals and finished dosage formulations, operating domestic distribution and export channels while performing contract manufacturing and outsourced production for third parties under its brands and subsidiaries. The company reported consolidated FY2026 revenue of Rs.703.06 crore and PAT of Rs.23.41 crore, with improving gross and EBITDA margins year-on-year; the June 2026 quarter showed revenue of Rs.174.41 crore and PAT of Rs.5.61 crore, signalling steady operational scale-up and incremental profitability for Sudarshan Pharma Industries Limited. Sudarshan Pharma Industries Limited has commissioned a Hyderabad manufacturing unit with a declared reactor capacity, R&D centre and has secured GMP and ISO 9001:2015 certifications for API and intermediate manufacturing, alongside a patent filing for sesamol in April 2026, reflecting investment in compliance and technologically enabled production. The firm is pursuing vertical integration to reduce import dependence, targeting regulated markets (Europe and USA) and diversifying exports across Asia, Middle East and African markets; Sudarshan Pharma Industries Limited aims to scale high-value APIs including oncology molecules and to leverage partner contracts and registrations to enter semi-regulated and regulated markets. Balance-sheet dynamics show high working capital and leverage concentration for Sudarshan Pharma Industries Limited: inventories at Rs.218.74 crore, trade receivables Rs.233.34 crore, short-term borrowings Rs.255.11 crore and cash of Rs.1.13 crore, highlighting liquidity and receivables management as immediate financial priorities while growth investments continue.
Over the past 52 weeks, Sudarshan Pharma Industries Ltd has traded between a low of ₹18.50 and a high of ₹42.79. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Sudarshan Pharma Industries Ltd has a market capitalization of approximately 780.18. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Sudarshan Pharma Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.18 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 780.18 Cr, Sudarshan Pharma Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Sudarshan Pharma Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Sudarshan Pharma Industries Ltd is 31.18. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Sudarshan Pharma Industries Limited is a specialty chemicals and pharmaceutical manufacturing, sourcing and trading company focused on APIs, advanced intermediates, specialty chemicals and finished dosage formulations, operating domestic distribution and export channels while performing contract manufacturing and outsourced production for third parties under its brands and subsidiaries.
The company reported consolidated FY2026 revenue of Rs.703.06 crore and PAT of Rs.23.41 crore, with improving gross and EBITDA margins year-on-year; the June 2026 quarter showed revenue of Rs.174.41 crore and PAT of Rs.5.61 crore, signalling steady operational scale-up and incremental profitability for Sudarshan Pharma Industries Limited.
Sudarshan Pharma Industries Limited has commissioned a Hyderabad manufacturing unit with a declared reactor capacity, R&D centre and has secured GMP and ISO 9001:2015 certifications for API and intermediate manufacturing, alongside a patent filing for sesamol in April 2026, reflecting investment in compliance and technologically enabled production.
The firm is pursuing vertical integration to reduce import dependence, targeting regulated markets (Europe and USA) and diversifying exports across Asia, Middle East and African markets; Sudarshan Pharma Industries Limited aims to scale high-value APIs including oncology molecules and to leverage partner contracts and registrations to enter semi-regulated and regulated markets.
Balance-sheet dynamics show high working capital and leverage concentration for Sudarshan Pharma Industries Limited: inventories at Rs.218.74 crore, trade receivables Rs.233.34 crore, short-term borrowings Rs.255.11 crore and cash of Rs.1.13 crore, highlighting liquidity and receivables management as immediate financial priorities while growth investments continue.
Chemicals & Petrochemicals
Specialty Chemicals
821 Cr
Low Risk
32.8
35.0
1.2
4.7
42.79
18.50
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
941.70 | 828 Cr | 22.83 | 3.28 | 0.32 | 11.74 | 17.68 | 11.89 | ||
31.25 | 780 Cr | 31.18 | 4.68 | 0.00 | 15.03 | 12.76 | 4.61 | ||
586.75 | 725 Cr | 24.33 | 5.13 | 0.26 | 21.08 | 29.09 | 15.32 | ||
197.70 | 724 Cr | 24.19 | 1.50 | 3.29 | 4.88 | 6.35 | 4.96 | ||
289.00 | 721 Cr | 18.03 | 2.90 | 0.87 | 11.01 | 14.50 | 8.97 | ||
191.20 | 709 Cr | 24.83 | 6.11 | 0.26 | 23.82 | 31.78 | 22.40 | ||
134.40 | 702 Cr | -48.65 | 1.56 | 0.00 | 0.32 | 3.17 | -2.25 | ||
| Median: 7 Co. | — | 197.70 | 724 Cr | 24.19 | 3.28 | 0.26 | 11.74 | 14.50 | 8.97 |
